Roche Licenses Alzheimer’s Compounds from Memory Pharmaceuticals
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 27 (Table of Contents)
Published: 2 Aug-2002
DOI: 10.3833/pdr.v2002.i27.1018 ISSN: 1756-7874
Section: Licensing
Abstract
Roche has acquired an exclusive worldwide license from Memory Pharmaceuticals to develop promising compounds for Alzheimer’s disease in a deal worth up to US$150 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS